Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SBFM with free AI briefings, catalyst countdowns, and dilution alerts.

SBFM · Sunshine Biopharma Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar. Closed at $2.60, 62% below $6.76, its close on the day of its Oct 9 registered direct offering. Of biotech stocks this far below their close on the day of a recent offering, 76% were lower 60 trading days later (median -29%). How we know
$20.6M Cash, Pro Forma
53.7mo Cash Runway
Follow SBFM by email Get an email when SBFM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SBFM, unsubscribe in one click. Privacy

📣 What SBFM Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Topical Corticosteroid Dermatitis, Atopic Phase 3 · NCT06554847 Completed
HEC585 Idiopathic Pulmonary Fibrosis (IPF) Phase 3 · NCT07082842 Recruiting
611 Dermatitis, Atopic Phase 3 · NCT07767253 Recruiting
Irinotecan Esophageal Cancer Phase 3 · NCT04415853 Recruiting
Larotinib Mesylate Esophageal Cancer Phase 3 · NCT04415853 Recruiting
Fludarabine Leukemia, Acute Myeloid (AML) Phase 3 · NCT05586074 Recruiting
Mitizodone Phosphate tablets Depressive Disorder, Major Phase 2/3 · NCT04984512 Recruiting
Clifutinib Leukemia, Acute Myeloid (AML) Phase 3 · NCT05586074 Recruiting
Idarubicin Leukemia, Acute Myeloid (AML) Phase 3 · NCT05586074 Recruiting
Recombinant Anti-interleukin-4 Receptor Alpha… Dermatitis, Atopic Phase 1/2 · NCT06324812 Completed
rHuEPO injection Chemotherapy-induced Anemia Phase 2 · NCT07891377 Not yet recruiting
SSGJ-613 100 mg Q12W Gout Arthritis Phase 2 · NCT07708181 Not yet recruiting
HEC585 dose B Progressive Fibrosing Interstitial Lung Disease (PF-ILD) /… Phase 2 · NCT05139719 Recruiting
HEC585 dose A Progressive Fibrosing Interstitial Lung Disease (PF-ILD) /… Phase 2 · NCT05139719 Recruiting
HEC53856 tablet Chemotherapy-induced Anemia Phase 2 · NCT07891377 Not yet recruiting
HEC169096 Advanced Solid Tumor Phase 1/2 · NCT05451602 Terminated

Also used in these trials (approved or third-party drugs, not SBFM's own candidates): Insulin Degludec, Cytarabine, Decitabine, Pirfenidone, Azacitidine, Colchicine, Gefitinib, Bevacizumab, Capecitabine, Oxaliplatin, Nintedanib, Efavirenz.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SBFM had $14.6M in cash and short-term investments on its Sep 30, 2026 balance sheet. Including the cash events since then, it holds about $20.6M pro forma, before operating spending after that date:

It burns about $1.2M/quarter from operations, an estimated runway of 53.7 months from Sep 30, 2026 at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SBFM files for a raise →

👥 Who Owns SBFM

Insiders 8.3% Other 5%+ holders 91.7% Institutions 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
CVI Investments, Inc. 5%+ holder (13G) 1,588,266 192.80% 2026-10-08
Mitchell P. Kopin Institution (13G, 5%+) 430,336 52.24% 2026-09-30
David Natan
Director
Insider 68,300 8.29% 2026-08-07
Michel Roy
Chief Commercial Officer
Insider 1 0.00% 2025-01-13

Share count 823,772 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SBFM picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SBFM and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.